The Mighty Mitochondria Are Unifying Organelles and Metabolic Hubs in Multiple Organs of Obesity, Insulin Resistance, Metabolic Syndrome, and Type 2 Diabetes: An Observational Ultrastructure Study
Overview
Chemistry
Molecular Biology
Authors
Affiliations
Mitochondria (Mt) are essential cellular organelles for the production of energy and thermogenesis. Mt also serve a host of functions in addition to energy production, which include cell signaling, metabolism, cell death, and aging. Due to the central role of Mt in metabolism as metabolic hubs, there has been renewed interest in how Mt impact metabolic pathways and multiple pathologies. This review shares multiple observational ultrastructural findings in multiple cells and organs to depict aberrant mitochondrial (aMt) remodeling in pre-clinical rodent models. Further, it is intended to show how remodeling of Mt are associated with obesity, insulin resistance, metabolic syndrome (MetS), and type 2 diabetes mellitus (T2DM). Specifically, Mt remodeling in hypertensive and insulin-resistant lean models (Ren2 rat models), lean mice with streptozotocin-induced diabetes, obesity models including diet-induced obesity, genetic leptin-deficient , and leptin receptor-deficient diabetic mice are examined. Indeed, aMt dysfunction and damage have been implicated in multiple pathogenic diseases. Manipulation of Mt such as the induction of Mt biogenesis coupled with improvement of mitophagy machinery may be helpful to remove leaky damaged aMt in order to prevent the complications associated with the generation of superoxide-derived reactive oxygen species and the subsequent reactive species interactome. A better understanding of Mt remodeling may help to unlock many of the mysteries in obesity, insulin resistance, MetS, T2DM, and the associated complications of diabetic end-organ disease.
Hayden M, Tyagi N Pharmaceuticals (Basel). 2025; 17(12.
PMID: 39770582 PMC: 11676759. DOI: 10.3390/ph17121741.
Mitochondrial Dysfunction in Systemic Lupus Erythematosus: Insights and Therapeutic Potential.
Poznyak A, Orekhov N, Churov A, Starodubtseva I, Beloyartsev D, Kovyanova T Diseases. 2024; 12(9).
PMID: 39329895 PMC: 11430897. DOI: 10.3390/diseases12090226.
Xhonneux I, Marei W, Meulders B, Andries S, Leroy J Front Physiol. 2024; 15:1354327.
PMID: 38585221 PMC: 10995298. DOI: 10.3389/fphys.2024.1354327.
Yin Y, Shan C, Han Q, Chen C, Wang Z, Huang Z Front Nutr. 2024; 10:1274078.
PMID: 38260086 PMC: 10800733. DOI: 10.3389/fnut.2023.1274078.
Primordial Drivers of Diabetes Heart Disease: Comprehensive Insights into Insulin Resistance.
Fan Y, Yan Z, Li T, Li A, Fan X, Qi Z Diabetes Metab J. 2024; 48(1):19-36.
PMID: 38173376 PMC: 10850268. DOI: 10.4093/dmj.2023.0110.